Irving Haber, DO
Pain Medicine · Terre Haute, INNPI 1144227596
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Biodelivery Sciences International, Inc. at 46.3% of the total. Reporting peaked in 2019 at $17,214 and has fallen 90.2% since, to $1,679 in 2025. Among pain medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 689 payments — averaging $41.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$13K
- Kaleo, Inc.$6K
- Radius Health, Inc.$1K
- Collegium Pharmaceutical, Inc.$1K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$693
- plus $5K from 44 others
What the payments were for
- Speaking & faculty fees$15,63055%
- Travel & lodging$2,3468%
- Food & beverage$10,25636%
- Education$3681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,600 in reported general payments places this provider in the 90th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 1,475 | $1,390,191 |
| NucyntaTapentadol Hcl | 494 | $677,585 |
| TymlosAbaloparatide | 209 | $551,842 |
| Nucynta ErTapentadol Hcl | 202 | $374,583 |
| HorizantGabapentin Enacarbil | 225 | $270,620 |
| Buprenorphine | 671 | $252,923 |
| ButransBuprenorphine | 171 | $81,538 |
| RelistorMethylnaltrexone Bromide | 32 | $75,197 |
| Tramadol Hcl ErTramadol Hcl | 878 | $68,550 |
| BelsomraSuvorexant | 154 | $65,420 |
| UbrelvyUbrogepant | 44 | $63,381 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,698 | $63,029 |
| OxycontinOxycodone Hcl | 88 | $59,190 |
| Teriparatide | 30 | $57,446 |
| Xtampza ErOxycodone Myristate | 71 | $55,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er, Xtampza Er | $1,236 | $2,497,6352,242 claims |
| Radius Health, Inc.Tymlos | $1,372 | $551,842209 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl, Buprenorphine-Naloxone | $35 | $297,4441,276 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $341 | $270,620225 claims |
| AbbVieUbrelvy, Linzess, Qulipta | $1,129 | $91,61185 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $693 | $75,19732 claims |
| MerckBelsomra | $112 | $65,420154 claims |
| Almatica Pharma LLCGralise | $168 | $49,31645 claims |
| PfizerNurtec Odt, Zavzpret | $138 | $32,65824 claims |
| AmgenProlia | $357 | $27,74016 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $70 | $17,03636 claims |
| Eisai Inc.Dayvigo | $320 | $12,16039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Terre Haute
- Derron WilsonCarmel$616K
- Kevin MacadaegCarmel$337K
- Andrew TrobridgeMuncie$253K
- Meredith LanghorstFishers$233K
- Abhishek DasMishawaka$186K
- Rajiv TewariFishers$140K
- John SwoffordIndianapolis$127K
- Neal ColemanMuncie$38K
- Matthew DevriesLafayette$37K
- Amer KaziGranger$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.